UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895"

Current oncology (Toronto), 2023-05, Vol.30 (5), p.5050-5053

2023

Volltextzugriff (PDF)

White Knuckling

Journal of clinical oncology, 2016-04, Vol.34 (12), p.1419-1420

Rayson, Daniel

2016

Volltextzugriff (PDF)

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5906-5910

2009

Volltextzugriff (PDF)

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Supportive care in cancer, 2016-01, Vol.24 (1), p.387-394

2016

Volltextzugriff (PDF)

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis

JAMA oncology, 2016-06, Vol.2 (6), p.751

2016

Volltextzugriff (PDF)

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

Breast cancer research and treatment, 2023-09, Vol.201 (2), p.257-264

2023

Volltextzugriff (PDF)

Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment

Supportive care in cancer, 2014-12, Vol.22 (12), p.3227-3234

2014

Volltextzugriff (PDF)

Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials

Cancer treatment reviews, 2012-10, Vol.38 (6), p.673-688

2012

Volltextzugriff (PDF)

The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines

Breast cancer research and treatment, 2008-02, Vol.107 (3), p.443-450

2008

Volltextzugriff (PDF)

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.153-162

2014

Volltextzugriff (PDF)

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

British journal of cancer, 2016-05, Vol.114 (10), p.1160-1164

2016

Volltextzugriff (PDF)

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100

Breast cancer research and treatment, 2008-09, Vol.111 (2), p.261-267

2008

Volltextzugriff (PDF)

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Breast cancer research and treatment, 2014-07, Vol.146 (2), p.421-427

2014

Volltextzugriff (PDF)

Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines

Cancer treatment reviews, 2008-08, Vol.34 (5), p.391-406

2008

Volltextzugriff (PDF)

Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy

Clinical breast cancer, 2012-02, Vol.12 (1), p.4-9

2012

Volltextzugriff (PDF)

Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000

Canadian Medical Association journal, 2004-03, Vol.170 (6), p.957-961

2004

Volltextzugriff (PDF)

Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model

American journal of clinical oncology, 2008-08, Vol.31 (4), p.369-374

2008

Volltextzugriff (PDF)

Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04

Canadian Medical Association journal, 2007-01, Vol.176 (3), p.327-332

2007

Volltextzugriff (PDF)

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

Breast cancer research and treatment, 2009-11, Vol.118 (2), p.377-383

2009

Volltextzugriff (PDF)

Adjuvant chemotherapy for women with young children: our patients as parents

Journal of clinical oncology, 2001-01, Vol.19 (1), p.279-281

Rayson, D

2001

Volltextzugriff (PDF)

Angiogenesis as a target for breast cancer therapy

Journal of mammary gland biology and neoplasia, 1999-10, Vol.4 (4), p.415-423

1999

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library

ThemaBreast Neoplasms - Drug Therapy

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Oncology
(21)
Science & Technology
(21)
Female
(20)
Breast Cancer
(14)
Aged
(11)
Middle Aged
(11)
Adult
(9)
Breast Neoplasms - Pathology
(9)
Cancer Therapies
(8)
Medicine
(8)
Medicine & Public Health
(8)
Treatment Outcome
(8)
Cancer Research
(7)
Chemotherapy
(6)
Risk Factors
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Breast Neoplasms - Epidemiology
(5)

13 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29 , 9891-9895"

White Knuckling

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment

Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials

The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines

Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy

Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000

Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model

Comparison of elapsed times from breast cancer detection to first adjuvant therapy in Nova Scotia in 1999/2000 and 2003/04

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

Adjuvant chemotherapy for women with young children: our patients as parents

Angiogenesis as a target for breast cancer therapy

Aktive Filter

Suchergebnisse filtern